Cd8(+) T-Cell Responses to Adeno-Associated Virus Capsid in Humans
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Hepatic adeno-associated virus (AAV)-serotype 2 mediated gene transfer results in transgene product expression that is sustained in experimental animals but not in human subjects. We hypothesize that this is caused by rejection of transduced hepatocytes by AAV capsid-specific memory CD8(+) T cells reactivated by AAV vectors. Here we show that healthy subjects carry AAV capsid-specific CD8(+) T cells and that AAV-mediated gene transfer results in their expansion. No such expansion occurs in mice after AAV-mediated gene transfer. In addition, we show that AAV-2 induced human T cells proliferate upon exposure to alternate AAV serotypes, indicating that other serotypes are unlikely to evade capsid-specific immune responses.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Detection of AAV components by the innate immune system also leads to the AAV-directed adaptive immune response and potential loss of transgene expression in transduced cells (Mingozzi et al., 2007; Xiang et al., 2020).”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Mingozzi et al., 2007
In the citing paper
“Early successes in this field were initially dampened by reports of patients who developed vector insertion-related leukemias directly linked to the viral platform used for transgene delivery11–18.”
From Clonal selection of hematopoietic stem cells after gene therapy for sickle cell disease (2023) · cites this paper as [12]
In the citing paper
“Evidence from early clinical trials, along with subsequent laboratory studies, suggest that CD8+ T cell responses against AAV capsid target transduced hepatocytes (16–18).”
From Effect of CpG Depletion of Vector Genome on CD8+ T Cell Responses in AAV Gene Therapy (2021) · cites this paper as [17]
In the citing paper
“An early clinical trial for the treatment of hemophilia, via i.v. delivery of recombinant AAV (rAAV), resulted in robust CD8 T cell responses and the loss of transgene expression, which was later shown to be mediated by capsid-specific T cell responses.”
From Modulating immune responses to AAV by expanded polyclonal T-regs and capsid specific chimeric antigen receptor T-regulatory cells (2021) · cites this paper as [5]
In the citing paper
“Although AAV infection is non-pathogenic in humans, initial exposure induces humoral and cellular anti-capsid response that are reactive to rAAV due to capsid similarity (4, 5).”
From Immunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies (2021) · cites this paper as [5]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Self-citationMemory CD8+ T cells vary in differentiation phenotype in different persistent virus infections
Appay, V., Dunbar, P. R., Callan, M., Klenerman, P., Gillespie, G. M. A., Papagno, L., Ogg, G. S., King, A., Lechner, F., Spina, C. A., et al. (2002) · Nature Medicine · doi:10.1038/nm0402-379 · Cited by 1,571
Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy
Gao, G.-P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J., & Wilson, J. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182412299 · Cited by 1,520
Snyder, R. O., Miao, C., Meuse, L., Tubb, J., Donahue, B. A., Lin, H.-F., Stafford, D. W., Patel, S., Thompson, A. R., Nichols, T., et al. (1999) · Nature Medicine · doi:10.1038/4751 · Cited by 409
Mount, J. D., Herzog, R. W., Tillson, D. M., Goodman, S. A., Robinson, N., McCleland, M. L., Bellinger, D., Nichols, T. C., Arruda, V. R., Lothrop, C. D., et al. (2002) · Blood · doi:10.1182/blood.v99.8.2670 · Cited by 339
Self-citationHeparin binding directs activation of T cells against adeno-associated virus serotype 2 capsid
Vandenberghe, L. H., Wang, L., Somanathan, S., Zhi, Y., Figueredo, J., Calcedo, R., Sanmiguel, J., Desai, R. A., Chen, C. S., Johnston, J., et al. (2006) · Nature Medicine · doi:10.1038/nm1445 · Cited by 208
Wang, L., Nichols, T. C., Read, M. S., Bellinger, D. A., & Verma, I. M. (2000) · Molecular Therapy · doi:10.1006/mthe.2000.0031 · Cited by 176
Identification of mouse AAV capsid-specific CD8+ T cell epitopes
Sabatino, D. E., Mingozzi, F., Hui, D. J., Chen, H., Colosi, P., Ertl, H. C. J., & High, K. A. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.09.009 · Cited by 91
Self-citation
Research works printed but not linked: 1
- Muzyczka, N. & Berns, K.I. Parvoviridae: The Viruses and Their Replication, 2327–2359 (Lippincott Williams & Wilkins, Philadelphia, 2001).
Cited by
Items 101–200 of 765
Odom, G. L., Gregorevic, P., Allen, J. M., Finn, E., & Chamberlain, J. S. (2008) · Molecular Therapy · doi:10.1038/mt.2008.149 · Cited by 121
“involved in immune activation following gene transfer is of great clinical significance and much progress has been made in this area.[29] In many DMD patients there is little or no dystrophin expression and in others the residual truncated protein produced in revertant myofibers lacks significant portions of the full…”
BackgroundIntracellular trafficking of adeno-associated virus (AAV) vectors: challenges and future directions
Riyad, J. M., & Weber, T. (2021) · Gene Therapy · doi:10.1038/s41434-021-00243-z · Cited by 118
Journey to the Center of the Cell: Tracing the Path of AAV Transduction
Dhungel, B. P., Bailey, C. G., & Rasko, J. E. J. (2021) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2020.09.010 · Cited by 122
Self-citationImmunogenicity assessment of AAV-based gene therapies: An IQ consortium industry white paper
Yang, T., Braun, M., Lembke, W., McBlane, F., Kamerud, J., DeWall, S. L., Tarcsa, E., Fang, X., Hofer, L., Kavita, U., et al. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.07.018 · Cited by 136
Immune responses to AAV-vectors, the Glybera example from bench to bedside
Ferreira, V., Petry, H., & Salmon, F. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00082 · Cited by 120
“The first observation of a cellular immune response induced by AAV-gene therapy to our knowledge was in patients with hemophilia B who were treated with an AAV-vector to deliver human coagulation factor IX (24, 27, 41, 42).”
MethodArruda, V. R., Stedman, H. H., Haurigot, V., Buchlis, G., Baila, S., Favaro, P., Chen, Y., Franck, H. G., Zhou, S., Wright, J. F., et al. (2010) · Blood · doi:10.1182/blood-2009-12-261156 · Cited by 117
Self-citationNew Hope for a MicroRNA Therapy for Liver Cancer
Rossi, J. J. (2009) · Cell · doi:10.1016/j.cell.2009.05.038 · Cited by 117
Hepatic Gene Transfer as a Means of Tolerance Induction to Transgene Products
LoDuca, P., Hoffman, B., & Herzog, R. (2009) · Current Gene Therapy · doi:10.2174/156652309787909490 · Cited by 114
“Vector administration correlated with a CTL response against viral capsid proteins, which has been hypothesized to have resulted in the killing of hepatocytes harboring input capsid antigen, which may be cross-presented by MHC I to CD8+ T cells [60].”
BackgroundGene therapy: a double-edged sword with great powers
Tang, R., & Xu, Z. (2020) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-020-03834-3 · Cited by 134
Finn, J. D., Hui, D., Downey, H. D., Dunn, D., Pien, G. C., Mingozzi, F., Zhou, S., & High, K. A. (2010) · Molecular Therapy · doi:10.1038/mt.2009.257 · Cited by 115
Self-citationSUMO-1 Gene Transfer Improves Cardiac Function in a Large-Animal Model of Heart Failure
Tilemann, L. M., Lee, A. A., Ishikawa, K., Agüero, J., Rapti, K., Santos‐Gallego, C. G., Kohlbrenner, E., Fish, K. M., Kho, C., & Hajjar, R. J. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006487 · Cited by 121
Clinical Gene Therapy for Neurodegenerative Diseases: Past, Present, and Future
Piguet, F., Alves, S., & Cartier, N. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.160 · Cited by 109
“Immune response Immune responses against the capsid and the transgene have emerged as serious obstacles for translation of AAV therapy to humans in peripheral tissues.(9,132) These are likely limited after direct injection of limited doses of viral vectors in the potentially immune-privileged brain.”
Challenges Posed by Immune Responses to AAV Vectors: Addressing Root Causes
Hamilton, B. A., & Wright, J. F. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.675897 · Cited by 117
“One explanation is that, in contrast to the direct processing for MHC class I presentation of viral antigens following their transcription and translation during natural virus infections, the capsid protein component of the rAAV dose must be processed via the indirect pathway (14, 28), which is less efficient.”
BackgroundSuperior In vivo Transduction of Human Hepatocytes Using Engineered AAV3 Capsid
Vercauteren, K., Hoffman, B. E., Zolotukhin, I., Keeler, G. D., Xiao, J. W., Basner-Tschakarjan, E., High, K. A., Ertl, H. C., Rice, C. M., Srivastava, A., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2016.61 · Cited by 114
Self-citationMEASE, P. J., WEI, N., FUDMAN, E. J., KIVITZ, A. J., SCHECHTMAN, J., TRAPP, R. G., HOBBS, K. F., GREENWALD, M., HOU, A., BOOKBINDER, S. A., et al. (2010) · The Journal of Rheumatology · doi:10.3899/jrheum.090817 · Cited by 114
“Any adverse event 23 (74) 28 (85) 24 (75) 25 (81) 77 (80) 27 (84) 26 (90) 29 (85) 82 (86) Gastrointestinal disorders 1 (3) 9 (27) 4 (13) 4 (13) 17 (18) 13 (41) 6 (21) 5 (15) 24 (25) General and administration site disorders 4 (13) 8 (24) 6 (19) 8 (26) 22 (23) 3 (9) 9 (31) 11 (32) 23 (24) Infections and infestations 13…”
Small But Increasingly Mighty: Latest Advances in AAV Vector Research, Design, and Evolution
Grimm, D., & Büning, H. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.172 · Cited by 112
“30,33 Accordingly, it is very tempting to postulate that use of rapamycin as an adjuvant might provide a dual benefit for liver-directed AAV gene therapies by (i) boosting the efficiency of gene transfer and (ii) concurrently alleviating adverse immune responses.”
Hareendran, S., Balakrishnan, B., Sen, D., Kumar, S., Srivastava, A., & Jayandharan, G. R. (2013) · Reviews in Medical Virology · doi:10.1002/rmv.1762 · Cited by 113
“Later, analysis of PBMNCs collected from a patient in the high dose group revealed a capsid-specific CD8+T-cell response that destroyedvector-transduced hepatocytes [13].”
BackgroundGoyenvalle, A., Babbs, A., Wright, J., Wilkins, V., Powell, D., García, L., & Davies, K. E. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds082 · Cited by 123
Mingozzi, F., Chen, Y., Murphy, S. L., Edmonson, S. C., Tai, A., Price, S. D., Metzger, M. E., Zhou, S., Wright, J. F., Donahue, R. E., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2012.84 · Cited by 112
Self-citationBaruteau, J., Waddington, S. N., Alexander, I. E., & Gissen, P. (2017) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-017-0053-3 · Cited by 110
“Unlike research animals, humans are exposed to wild type AAV infections generating anti-AAV memory T cells, which are reactivated at the time of vector exposure (Mingozzi et al 2007).”
BackgroundSeitz, I. P., Michalakis, S., Wilhelm, B., Reichel, F. F., Ochakovski, G. A., Zrenner, E., Ueffing, M., Biel, M., Wissinger, B., Bartz-Schmidt, K. U., et al. (2017) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.17-22473 · Cited by 108
“However, these trials have shown that systemic exposure to significant numbers of any rAAV serotype can induce humoral and cellular immune response followed by directed removal of successfully transduced target cells by cytotoxic T lymphocytes.(21) Previous studies in large animal models have demonstrated that rAAV8 g…”
Ruzo, A., Marcó, S., García, M., Villacampa, P., Ribera, A., Ayuso, E., Maggioni, L., Mingozzi, F., Haurigot, V., & Bosch, F. (2012) · Human Gene Therapy · doi:10.1089/hum.2012.029 · Cited by 104
“…may also trigger the activation of capsid-specific CD8 + T cell responses directed against the viral capsid in a dose-dependent manner (Manno et al. , 2006; Mingozzi et al. , 2007; Mingozzi et al. , 2009; Nathwani et al. , 2011), which may or may not affect the CNS (Lowenstein et al. , 2007).”
Self-citationSchirmbeck, R., Reimann, J., Kochanek, S., & Kreppel, F. (2008) · Molecular Therapy · doi:10.1038/mt.2008.141 · Cited by 114
Therapeutic approaches to muscular dystrophy
Goyenvalle, A., Seto, J. T., Davies, K. E., & Chamberlain, J. S. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr105 · Cited by 130
“Capsid-specific T-cell responses are also sometimes primed by the delivery of the rAAV vector to muscle (36,56), but this does not necessarily cause loss of transgene expression (56).”
BackgroundBouquet, C., Vignal Clermont, C., Galy, A., Fitoussi, S., Blouin, L., Munk, M. R., Valero, S., Meunier, S., Katz, B., Sahel, J. A., et al. (2019) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2018.6902 · Cited by 104
Exposure to wild-type AAV drives distinct capsid immunity profiles in humans
Kuranda, K., Jean-Alphonse, P., Leborgne, C., Hardet, R., Collaud, F., Marmier, S., Costa Verdera, H., Ronzitti, G., Veron, P., & Mingozzi, F. (2018) · Journal of Clinical Investigation · doi:10.1172/jci122372 · Cited by 104
“Our study supports this hypothesis, as it shows that CD8+ T cells restimulated with the VP1372–380 epitope (22) secrete cytotoxic granules (CD107a) in the presence of target cells, without concomitant IFN-γ secretion.”
BackgroundMethodResultInfluentialSelf-citationNienhuis, A. W., Nathwani, A. C., & Davidoff, A. M. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.033 · Cited by 99
Koilkonda, R. D., Yu, H., Chou, T.-H., Feuer, W. J., Ruggeri, M., Porciatti, V., Tse, D., Hauswirth, W. W., Chiodo, V., Boye, S. L., et al. (2014) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2013.7630 · Cited by 103
Strategy to detect pre-existing immunity to AAV gene therapy
Falese, L., Sandza, K., Yates, B., Triffault, S., Gangar, S., Long, B., Tsuruda, L., Carter, B., Vettermann, C., Zoog, S. J., et al. (2017) · Gene Therapy · doi:10.1038/gt.2017.95 · Cited by 101
Diverse IgG subclass responses to adeno‐associated virus infection and vector administration
Murphy, S. L., Li, H., Mingozzi, F., Sabatino, D. E., Hui, D. J., Edmonson, S. A., & High, K. A. (2009) · Journal of Medical Virology · doi:10.1002/jmv.21360 · Cited by 101
“CD8+ T cells that respond to AAV capsid epitopes were also found among normal human subject PBMCs [Mingozzi et al., 2007].”
BackgroundSelf-citationMashel, T. V., Tarakanchikova, Y. V., Muslimov, A. R., Zyuzin, M. V., Timin, A. S., Lepik, K. V., & Fehse, B. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120282 · Cited by 105
Cell-Mediated Immunity to AAV Vectors, Evolving Concepts and Potential Solutions
Basner-Tschakarjan, E., & Mingozzi, F. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00350 · Cited by 95
“In this study, upon AAV gene transfer to liver, two subjects developed transient elevation of liver enzymes and loss of FIX transgene expression around week 4 post vector delivery due to the immune rejection of transduced hepatocytes mediated by capsid-specific CD8 T cells (74).”
BackgroundMethodInfluentialSelf-citationCapsid-specific removal of circulating antibodies to adeno-associated virus vectors
Bertin, B., Veron, P., Leborgne, C., Deschamps, J.-Y., Moullec, S., Fromes, Y., Collaud, F., Boutin, S., Latournerie, V., van Wittenberghe, L., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-57893-z · Cited by 100
Self-citationThe potential of adeno-associated viral vectors for gene delivery to muscle tissue
Wang, D., Zhong, L., Nahid, M. A., & Gao, G. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.871258 · Cited by 98
“In support of the presence of capsid-specific memory CD8 T cells in general population, previous studies have shown that AAV2 capsid-specific CD8 T cells in healthy donors are capable of quick expansion and mediating potent cytolytic activity against cells displaying the capsid antigen [109].”
InfluentialLock, M., Alvira, M. R., & Wilson, J. M. (2012) · Human Gene Therapy Methods · doi:10.1089/hgtb.2011.217 · Cited by 99
“One example of such a reaction was observed during a clinical trial for the treatment of hemophilia with an AAV2 vector bearing the human factor IX gene (Mingozzi et al. , 2007).”
Efficient whole brain transduction by systemic infusion of minimally purified AAV-PHP.eB
Konno, A., & Hirai, H. (2020) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2020.108914 · Cited by 101
Gene therapy of inherited diseases
Fischer, A., & Cavazzana, M. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60874-0 · Cited by 117
Murphy, S. L., & High, K. A. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06942.x · Cited by 112
“The kinetics of the T-cell response in subject G were mapped with this reagent and shown to overlap with the peak of serum transaminases (Mingozzi et al, 2007).”
BackgroundMethodSelf-citationAAVs Anatomy: Roadmap for Optimizing Vectors for Translational Success
M. Mitchell, A., C. Nicolson, S., K. Warischalk, J., & Jude Samulski, R. (2010) · Current Gene Therapy · doi:10.2174/156652310793180706 · Cited by 96
Understanding AAV vector immunogenicity: from particle to patient
Dhungel, B. P., Winburn, I. C., Pereira, C. D. F., Huang, K., Chhabra, A., & Rasko, J. E. J. (2024) · Theranostics · doi:10.7150/thno.89380 · Cited by 101
“The degradation and presentation of Cap on major histocompatibility complex (MHC) class I molecules may result in the clearance of transduced cells by capsid-specific cytotoxic CD8 + T cells [44] and presentation of capsid proteins on MHC class II molecules [11, 42].”
BackgroundSelf-citationAslanidi, G. V., Rivers, A. E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., & Srivastava, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059142 · Cited by 95
“IX was short-lived due to a cytotoxic T cell (CTL) response against AAV2 capsids [9,10,11].”
BackgroundSalmon, F., Grosios, K., & Petry, H. (2014) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2014.852065 · Cited by 93
Modulation of immune responses in lentiviral vector-mediated gene transfer
Annoni, A., Gregori, S., Naldini, L., & Cantore, A. (2018) · Cellular Immunology · doi:10.1016/j.cellimm.2018.04.012 · Cited by 99
AAV-mediated gene transfer for the treatment of hemophilia B: problems and prospects
Hasbrouck, N. C., & High, K. A. (2008) · Gene Therapy · doi:10.1038/gt.2008.71 · Cited by 100
Self-citationAyuso, E., Blouin, V., Lock, M., McGorray, S., Leon, X., Alvira, M. R., Auricchio, A., Bucher, S., Chtarto, A., Clark, K. R., et al. (2014) · Human Gene Therapy · doi:10.1089/hum.2014.057 · Cited by 94
Ertl, H. C. J., & High, K. A. (2017) · Human Gene Therapy · doi:10.1089/hum.2016.172 · Cited by 94
“15 The argument was made that cryptic epitopes within the F9 gene triggered a T-cell response in the rAAV2-FIX trial.”
Self-citationDosage thresholds and influence of transgene cassette in adeno-associated virus–related toxicity
Khabou, H., Cordeau, C., Pacot, L., Fisson, S., & Dalkara, D. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.144 · Cited by 93
Investigation of the Cause of Death in a Gene-Therapy Trial
Frank, K. M., Hogarth, D. K., Miller, J. L., Mandal, S., Mease, P. J., Samulski, R. J., Weisgerber, G. A., & Hart, J. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0801066 · Cited by 72
An AAV Dual Vector Strategy Ameliorates the Stargardt Phenotype in Adult Abca4 −/− Mice
McClements, M. E., Barnard, A. R., Singh, M. S., Charbel Issa, P., Jiang, Z., Radu, R. A., & MacLaren, R. E. (2019) · Human Gene Therapy · doi:10.1089/hum.2018.156 · Cited by 92
Cao, O., Hoffman, B. E., Moghimi, B., Nayak, S., Cooper, M., Zhou, S., Ertl, H. C., High, K. A., & Herzog, R. W. (2009) · Molecular Therapy · doi:10.1038/mt.2009.159 · Cited by 92
Self-citationZerah, M., Piguet, F., Colle, M.-A., Raoul, S., Deschamps, J.-Y., Deniaud, J., Gautier, B., Toulgoat, F., Bieche, I., Laurendeau, I., et al. (2015) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2014.139 · Cited by 92
“In addition, AAV vector and/or ARSA enzyme can be transported along axons, expanding the expression of the therapeutic enzyme within the brain (Castle et al., 2014; Cearley and Wolfe 2006, 2007; Chen et al., 2006; Dodiya et al., 2010; Kells et al., 2009; Luca et al., 2005; Passini et al., 2002).”
Potential of AAV vectors in the treatment of metabolic disease
Alexander, I. E., Cunningham, S. C., Logan, G. J., & Christodoulou, J. (2008) · Gene Therapy · doi:10.1038/gt.2008.64 · Cited by 94
D'Costa, S., Blouin, V., Broucque, F., Penaud-Budloo, M., Fçranois, A., Perez, I. C., Le Bec, C., Moullier, P., Snyder, R. O., & Ayuso, E. (2016) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2016.19 · Cited by 89
Gene Therapy in Patients with the Crigler–Najjar Syndrome
D’Antiga, L., Beuers, U. H., Ronzitti, G., Brunetti‐Pierri, N., Baumann, U., Giorgio, A. D., Aronson, S. J., Hubert, A., Romano, R., Junge, N., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2214084 · Cited by 94
Self-citationEvading the immune response upon in vivo gene therapy with viral vectors.
Sack, B. K., & Herzog, R. W. (2009) · PubMed · Cited by 107
Hauck, B., Murphy, S. L., Smith, P. H., Qu, G., Liu, X., Zelenaia, O., Mingozzi, F., Sommer, J. M., High, K. A., & Wright, J. F. (2009) · Molecular Therapy · doi:10.1038/mt.2008.227 · Cited by 88
Self-citationStieger, K., Schroeder, J., Provost, N., Mendes-Madeira, A., Belbellaa, B., Meur, G. L., Weber, M., Deschamps, J.-Y., Lorenz, B., Moullier, P., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2008.283 · Cited by 88
T Cell-Mediated Immune Responses to AAV and AAV Vectors
Ertl, H. C. J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.666666 · Cited by 88
“T cell epitopes are conserved between several AAV serotypes (9) and several studies reported no correlations between antibody and CD8 T cell responses (32, 35).”
BackgroundSelf-citationLin, S.-W., Hensley, S. E., Tatsis, N., Lasaro, M. O., & Ertl, H. C. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci33138 · Cited by 88
“Humans commonly carry neutralizing antibodies to human serotypes of AAV such as AAV2 and AAV1 as a result of natural infections (61), and such antibodies have been shown in gene therapy trials to reduce gene transfer (61, 62).”
BackgroundSelf-citationVeron, P., Leborgne, C., Monteilhet, V., Boutin, S., Martin, S., Moullier, P., & Masurier, C. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200620 · Cited by 88
“The frequency of circulating capsid-specific T cells was determined by IFN-g ELISPOT in which cells were stimulated with AAV-specific overlapping peptides (12, 16).”
BackgroundMethodInfluentialImmunization delivered by lentiviral vectors for cancer and infectious diseases
Hu, B., Tai, A., & Wang, P. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00967.x · Cited by 89
Immune Responses to Lentiviral Vectors
Follenzi, A., Santambrogio, L., & Annoni, A. (2007) · Current Gene Therapy · doi:10.2174/156652307782151515 · Cited by 87
Monahan, P. E., Négrier, C., Tarantino, M., Valentino, L. A., & Mingozzi, F. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10112471 · Cited by 85
“Similar to the case with NAbs, there is evidence for cross-reactivity in cytotoxic T-lymphocyte (CTL) responses across multiple AAV serotypes [4,16,71].”
BackgroundResultInfluentialSelf-citationArthritis gene therapy's first death
Evans, C. H., Ghivizzani, S. C., & Robbins, P. D. (2008) · Arthritis Research & Therapy · doi:10.1186/ar2411 · Cited by 87
Dickerson, R., Argento, C., Pieracci, J. P., & Bakhshayeshi, M. (2020) · Biotechnology Journal · doi:10.1002/biot.202000015 · Cited by 88
Critical challenges and advances in recombinant adeno‐associated virus (rAAV) biomanufacturing
Fu, Q., Polanco, A., Lee, Y. S., & Yoon, S. (2023) · Biotechnology and Bioengineering · doi:10.1002/bit.28412 · Cited by 79
“Purification process that cannot substantially remove this product‐related impurity can result in exacerbated immune responses (Manno et al., 2006; Mingozzi et al., 2007) and reduced transduction efficiency (Parker et al., 2003).”
BackgroundInfluentialNair, N., Rincon, M. Y., Evens, H., Sarcar, S., Dastidar, S., Samara-Kuko, E., Ghandeharian, O., Man Viecelli, H., Thöny, B., De Bleser, P., et al. (2014) · Blood · doi:10.1182/blood-2013-10-534032 · Cited by 84
AAV capsid CD8+ T-cell epitopes are highly conserved across AAV serotypes
Hui, D. J., Edmonson, S. C., Podsakoff, G. M., Pien, G. C., Ivanciu, L., Camire, R. M., Ertl, H., Mingozzi, F., High, K. A., & Basner-Tschakarjan, E. (2015) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2015.29 · Cited by 84
Self-citationGene therapy for haemophilia: a long and winding road
High, K. A. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2011.04369.x · Cited by 87
Self-citationWright, J. F. (2021) · Biotechnology Journal · doi:10.1002/biot.202000022 · Cited by 82
Li, H., Lasaro, M. O., Jia, B., Lin, S. W., Haut, L. H., High, K. A., & Ertl, H. C. (2011) · Molecular Therapy · doi:10.1038/mt.2011.81 · Cited by 83
Self-citationKumar, S. R. P., Hoffman, B. E., Terhorst, C., de Jong, Y. P., & Herzog, R. W. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.02.014 · Cited by 83
“In the initial clinical trial on hepatic AAV2 gene transfer for hemophilia, a CD8 T cell response against the viral capsid was identified as the cause for loss of hepatocytes expressing the therapeutic transgene.(25,26) This response occurred approximately 1 month after gene transfer in those patients receiving the hi…”
BackgroundGene and cell‐mediated therapies for muscular dystrophy
Konieczny, P., Swiderski, K., & Chamberlain, J. S. (2013) · Muscle & Nerve · doi:10.1002/mus.23738 · Cited by 97
“Human clinical trials using rAAV 1 and 2 have also led to the development of T-cell mediated immune responses against the viral capsids.(106,107) It will be critically important to assess whether transient immunosuppressive strategies, such as those pioneered in the canine model of DMD, will effectively block these re…”
BackgroundChhabra, A., Bashirians, G., Petropoulos, C. J., Wrin, T., Paliwal, Y., Henstock, P. V., Somanathan, S., Pereira, C. D. F., Winburn, I. C., & Rasko, J. E. J. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101273 · Cited by 92
Self-citationPrasad, S., Dimmock, D. P., Greenberg, B., Walia, J. S., Sadhu, C., Tavakkoli, F., & Lipshutz, G. S. (2022) · Human Gene Therapy · doi:10.1089/hum.2022.138 · Cited by 81
Effect of CpG Depletion of Vector Genome on CD8+ T Cell Responses in AAV Gene Therapy
Bertolini, T. B., Shirley, J. L., Zolotukhin, I., Li, X., Kaisho, T., Xiao, W., Kumar, S. R. P., & Herzog, R. W. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.672449 · Cited by 80
Gene therapy for retinal disease
McClements, M. E., & MacLaren, R. E. (2013) · Translational Research · doi:10.1016/j.trsl.2012.12.007 · Cited by 80
Chowdhury, E. A., Meno‐Tetang, G. M. L., Chang, H. Y., Wu, S., Huang, H. W., Jamier, T., Chandran, J. S., & Shah, D. K. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.01.017 · Cited by 82
Chuah, M. K., Petrus, I., De Bleser, P., Le Guiner, C., Gernoux, G., Adjali, O., Nair, N., Willems, J., Evens, H., Rincon, M. Y., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.114 · Cited by 80
Self-citationLi, S., Ling, C., Zhong, L., Li, M., Su, Q., He, R., Tang, Q., Greiner, D. L., Shultz, L. D., Brehm, M. A., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2015.174 · Cited by 77
Cellular immune response to cryptic epitopes during therapeutic gene transfer
Li, C., Goudy, K., Hirsch, M., Asokan, A., Fan, Y., Alexander, J., Sun, J., Monahan, P., Seiber, D., Sidney, J., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0902269106 · Cited by 79
“Lastly, AAV2 capsids do not elicit a CTL response in B0702 transgenic mice after muscle injection of a high dose of AAV2 vectors (8).”
BackgroundShirley, J. L., Keeler, G. D., Sherman, A., Zolotukhin, I., Markusic, D. M., Hoffman, B. E., Morel, L. M., Wallet, M. A., Terhorst, C., & Herzog, R. W. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.11.011 · Cited by 79
Joshi, P. R. H., Bernier, A., Moço, P. D., Schrag, J. D., Chahal, P. S., & Kamen, A. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.03.016 · Cited by 83
“Molecular Therapy: Methods & This is an open access article under the CC BY-NCreducing transduction efficiency (while being in excess) through competition for receptor binding,(6) inducing dose-dependent capsid-neutralizing antibody response,(7) and cytotoxic T-lymphocyte-mediated destruction of transduced cells displ…”
BackgroundHigh Levels of Frataxin Overexpression Lead to Mitochondrial and Cardiac Toxicity in Mouse Models
Belbellaa, B., Reutenauer, L., Messaddeq, N., Monassier, L., & Puccio, H. M. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.08.018 · Cited by 84
“In the current study, we did not investigate the potential involvement of the innate or adaptive immune response against the vector, transgene, and/or transduced cells.(35,36,52,53) It is likely that the treated mice developed a humoral response against the capsid, including neutralizing antibodies, as shown previousl…”
BackgroundResultGene therapy for liver diseases — progress and challenges
Zabaleta, N., Unzu, C., Weber, N. D., & González‐Aseguinolaza, G. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00729-0 · Cited by 80
Mimuro, J., Mizukami, H., Shima, M., Matsushita, T., Taki, M., Muto, S., Higasa, S., Sakai, M., Ohmori, T., Madoiwa, S., et al. (2014) · Journal of Medical Virology · doi:10.1002/jmv.23818 · Cited by 77
“Elimination of AAV vector-transduced cells by host T cells is another concern associated with AAV vector-based gene therapy [Manno et al., 2006; Mingozzi et al., 2007; Li et al., 2009; Mingozzi et al., 2009; Mingozzi and High, 2011].”
BackgroundWang, Z., Storb, R., Halbert, C. L., Banks, G. B., Butts, T. M., Finn, E. E., Allen, J. M., Miller, A. D., Chamberlain, J. S., & Tapscott, S. J. (2012) · Molecular Therapy · doi:10.1038/mt.2012.111 · Cited by 78
Schnödt, M., & Büning, H. (2017) · Human Gene Therapy Methods · doi:10.1089/hgtb.2016.188 · Cited by 77
“, the presence of empty capsids is regarded as detrimental, as they present a source of unnecessary, potentially antigenic material, possibly inducing or elevating capsidtriggered anti-AAV innate and adaptive immune responses.(34,35) The latter resulted in liverdirected human clinical trials in loss(36) or significant…”
Long, B. R., Veron, P., Kuranda, K., Hardet, R., Mitchell, N., Hayes, G. M., Wong, W. Y., Lau, K., Li, M., Hock, M. B., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.008 · Cited by 76
Self-citationProgress and prospects: gene therapy for genetic diseases with helper-dependent adenoviral vectors
Brunetti‐Pierri, N., & Ng, P. (2008) · Gene Therapy · doi:10.1038/gt.2008.14 · Cited by 77
Adeno-associated viral vectors for the treatment of hemophilia
High, K. A., & Anguela, X. M. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddv475 · Cited by 73
“Both of these events were attributed to the destruction of transduced hepatocytes by AAV capsid-specific memory CD8+ T cells (19).”
BackgroundSelf-citationNear-perfect infectivity of wild-type AAV as benchmark for infectivity of recombinant AAV vectors
Zeltner, N., Kohlbrenner, E., Clément, N., Weber, T., & Linden, R. M. (2010) · Gene Therapy · doi:10.1038/gt.2010.27 · Cited by 69
Emerging strategies for cell and gene therapy of the muscular dystrophies
Muir, L. A., & Chamberlain, J. S. (2009) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399409001100 · Cited by 76
Current status of haemophilia gene therapy
High, K. H., Nathwani, A., Spencer, T., & Lillicrap, D. (2014) · Haemophilia · doi:10.1111/hae.12411 · Cited by 73
Self-citationDaci, R., & Flotte, T. R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25021050 · Cited by 81
“The therapeutic effect of the desired transgene protein may be eliminated by either developing antibodies to the transgene protein or by using cytotoxic T cells to remove the transduced cells [80,81].”
BackgroundDevelopment of gene therapy for blood disorders
Nienhuis, A. W. (2008) · Blood · doi:10.1182/blood-2007-11-078121 · Cited by 80
Adeno-Associated Viruses (AAV) and Host Immunity – A Race Between the Hare and the Hedgehog
Rapti, K., & Grimm, D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.753467 · Cited by 79
“It was further established that humans carry capsid-specific T-cells against AAVs (38, 139), and that the elicited immune response is dose-dependent (35, 101).”
BackgroundJayandharan, G. R., Aslanidi, G., Martino, A. T., Jahn, S. C., Perrin, G. Q., Herzog, R. W., & Srivastava, A. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1012753108 · Cited by 72
“This CD8 T-cell–mediated immune response was unexpected, as it had not been observed in any preclinical animal models (12).”
BackgroundRetractedRonzitti, G., Bortolussi, G., van Dijk, R., Collaud, F., Charles, S., Leborgne, C., Vidal, P., Martin, S., Gjata, B., Sola, M. S., et al. (2016) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2016.49 · Cited by 69
Self-citationGenome engineering: a new approach to gene therapy for neuromuscular disorders
Nelson, C. E., Robinson-Hamm, J. N., & Gersbach, C. A. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.126 · Cited by 77
Metadata
- Authors
- Mingozzi, F., Maus, M. V., Hui, D. J., Sabatino, D. E., Murphy, S. L., Rasko, J. E. J., Ragni, M. V., Manno, C. S., Sommer, J., Jiang, H., Pierce, G. F., Ertl, H. C. J., & High, K. A.
- Affiliations
- Children's Hospital of Philadelphia (US)
- The University of Sydney (AU)
- Hemophilia Center of Western Pennsylvania (US)
- The Wistar Institute (US)
- Corresponding author
- High, Katherine A
- ORCID
- Venue
- Nature Medicine
- Published
- 2007-03-18
- Volume
- 13
- Issue
- 4
- Pages
- 419-422
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2007261697
- Cited by
- 748
- References
- 8
- Citations by year
- 2026: 34 · 2025: 43 · 2024: 43 · 2023: 41 · 2022: 34 · 2021: 58 · 2020: 43 · 2019: 40 · 2018: 28 · 2017: 38 · 2016: 24 · 2015: 40 · 2014: 41 · 2013: 37 · 2012: 40
- FWCI
- 22.15
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (1f32hl069647-01)
- National Heart, Lung, and Blood Institute (F32 HL69647, P01HL078810, T32HL007439)
- National Institute of Allergy and Infectious Diseases (P30AI045008)
- National Institute of Diabetes and Digestive and Kidney Diseases (T32DK007748)
- National Center for Research Resources (M01RR000056, M01RR000240)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- adeno-associated virus, AAV capsid, CD8+ T cells, AAV serotype 2, gene transfer, T cell memory, T cell proliferation
- MeSH terms
- Dependovirus, Animals, Capsid, Humans, Lymphocyte Activation, Parvoviridae Infections, Peptides, Gene Transfer Techniques, CD8-Positive T-Lymphocytes, Hepatocytes, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.